Compare Quest Diagnostics Inc (DGX) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Fox Corp Class A — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Fox Corp Class A trades at $62.41 (market cap $25.36B). The key difference: Quest Diagnostics Inc and Fox Corp Class A are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Fox Corp Class A for 34 Days on average.
| DGX | FOXA | |
|---|---|---|
Market Cap | $25.48B | $25.36B |
Volume | 941,866 | 2,566,954 |
Sector | Health | Media |
52-Week High | $247.45 | $76.11 |
52-Week Low | $173.49 | $48.79 |
Typical Hold Time | 56 Days | 34 Days |
Enterprise Value | $31.23B | $28.72B |
Dividend Yield | 1.49% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
FOXA trades at $63.57, up 1.39% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust 2025 results with revenue of $16.3B and net income of $2.26B, supported by solid cash flow. Analyst consensus is a Buy with a $72.00 price target, and recent news highlights the ongoing $22B Roku acquisition process and insider buying by CEO Lachlan Murdoch.
The outlook is positive given strong fundamentals and analyst support, but risks include regulatory scrutiny of the Roku deal and a projected net cash flow decline in 2026. The stock offers value with a P/E of 16.55 and growth potential, though investors must monitor deal approval and competitive pressures in media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
